Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indivior Pharmaceuticals Inc. Common Stock vs Rocket Lab USA Inc — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.01 (market cap $4.18B), while Rocket Lab USA Inc trades at $54.49 (market cap $41.06B). The key difference: Rocket Lab USA Inc is far larger — about 9.8× Indivior Pharmaceuticals Inc. Common Stock's market cap, and Indivior Pharmaceuticals Inc. Common Stock is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and Rocket Lab USA Inc for 29 Days on average.
| INDV | RKLB | |
|---|---|---|
Market Cap | $4.18B | $41.06B |
Volume | 1,819,746 | 15,510,966 |
Sector | Health | Industrials |
52-Week High | $41.83 | $150.23 |
52-Week Low | $24.09 | $39.48 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $4.47B | $38.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rocket Lab (RKLB) trades at $64.22, down 2.27% today, amid bearish technical signals despite strong analyst support. The company recently secured its largest-ever commercial Electron deal with Synspective for 20 launches, boosting its backlog past 100 missions. Financially, RKLB shows robust revenue growth ($602M in 2025, $769M projected for 2026) but remains unprofitable with a net income margin of -21.51%. Valuation metrics appear elevated with a P/S ratio of 48.79.
The outlook balances significant growth potential from a expanding launch backlog against persistent profitability challenges and competitive threats from SpaceX. Analyst consensus is strongly bullish with a $107 price target, but investors face risks from cash burn, execution hurdles, and high valuation multiples. The stock's near-term direction will hinge on Neutron rocket development and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indivior Pharmaceuticals Inc. Common Stock
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
